Prediction Value of TWEAK/Fn14 in Crohn’s Disease with Intestinal Fibrosis

XU Ting, YANG Yan, ZHAO Li. et al

Abstract

To investigate the expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/ fibroblast growth factorinducible 14 (Fn14) in the serum and colon tissue of Crohn’s disease (CD) and to elucidate whether the expression of TWEAK/Fn14 can be used as an indicator for intestinal fibrosis. Methods Blood samples from 67 CD patients and 33 healthy controls were collected to measure the level of TWEAK by ELISA. Meanwhile, colon samples from 29 CD patients received colectomy and the normal colon tissues from 15 patients with colon cancer were included. The expression of TWEAK and Fn14 in colon samples was analyzed by immunohistochemistry (IHC). The number of the cells with Fn14， αsmooth muscle actin (αSMA) double positive was measured by immunofluorescent double staining. Results The level of serum TWEAK in CD patients was higher than that in healthy controls ( P<0.01), which was positive correlated with colectomy ( r=0.295, P=0.015), intestinal stenosis ( r=0.290, P=0.017) and intestinal obstruction ( r=0.453, P=0.000 1). ROC analysis displayed the area under the curve of serum TWEAK for predicting intestinal stenosis in CD patients was 0.67 (95%CI 0.540.80， P=0.020). IHC results showed that the expression of TWEAK and Fn14 were increased in colon samples from CD patients with intestinal obstruction ( P<0.05). The number of Fn14 and αSMA positive cells was significantly increased in CD patients with intestinal obstruction ( P<0.05). Conclusion TWEAK/Fn14 pathway may play an important role in CD related intestinal fibrosis.

 

Keywords: Crohn’s disease, Intestinal fibrosis TWEAK, Fn14 

 

Full Text:

PDF


References


LATEI-LAG, DI GREGORIO J. FLATI V, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol«2015,50( 1) :53-65.

PAINE E, SHEN B. Endoscopic therapy in inflammatory bowel diseases (with videos). Gastrointest Endosc, 2013, 78 (6):819-835.

DOHI T, BURKLY LC. The TWEAK/Fnl4 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol, 2012, 92(2);265-279.

К A WASH IMA R. KAWAMURA YI, OSHIO T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fnl4 in mice-а pathway associated with ulcerative colitis. Gastroenterology,2011,141(6) ; 2119-2129. e8[2015-01-12]. https://doi. org/10. 1053/j. gastro. 2011. 08. 040.

DOHI T, BORODOVSKY A, WU P. et al. TWEAK/Fnl4 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.Gastroenterology, 2009,136 (3): 912-923.

DOHI T, К AWASH IMA R, KAWAMURA YI, et al. Pathological activation of canonical nuclear-factor kappaB by synergy of tumor necrosis factor alpha and TNF-like weak inducer of apoptosis in mouse acute colitis. Cytokine,2014 ,69 (1):14-21.

SON A, OSHIO T, KAWAMURA YI, et al. TWEAK/ Fnl4 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol,2013,6(6) : 1131-1142.

NOVOYATLEVA T. SCHYMURA Y. JANSSEN W, et al. Deletion of Fnl4 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol,2013 ,108(2) :325 [ 2017-01-23 ]. https: // www. ncbi. nlm. nih. gov/pmc/ articles/PMC3597271/. doi: 10. 1007/s00395-012-0325-x.

TIRNITZ-PARKER JE. VIEBAHN CS, JAKUBOWSKI A, et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology, 2010, 52(1):291-302.

НОТТА K. SHO M, YAMATO I, et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int, 2011,79(2): 179-188.

JAIN M. JAKUBOWSKI A, GUI L, et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation,2009 , 119( 15); 2058-2068.

UCERO AC, BENITO-MARTIN A, FUENTES-CALVO I, et al. TNF-related weak inducer of apoptosis ( TWEAK ) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta, 2013, 1832 (10): 1744-1755.

KAPLAN M, YUKSEL M, ATES I. et al. Are sTWEAK and IL-17A levels in inflammatory bowel disease associated with disease activity and etiopathogenesis? Inflamm Bowel Dis, 2016,22(3) :615-622.

HUANG W, XIAO DZ, WANG Y, et al. Fnl4 promotes differentiation of human mesenchymal stem cells into heart valvular interstitial cells by phenotypic characterization. J Cell Physiol ,2014,229(5): 580-587.

CHEN HN, WANG DJ, REN MY, et al. TWEAK/Fnl4 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кВ pathway. Mol Biol Rep, 2012,39(8):8231-8241.

ITOIGAWA Y, HARADA N, HARADA S, et al. TWEAK enhances TGF-beta-induced epithelial-mesenchymal transition in human bronchial epithelial cells. Respir Res, 2015 ,16; 48. doi: 10. 1186/sl 2931-015-0207-5.

CHICHEPORTICHE Y, CHICHEPORTICHE R. SIZING I, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res .2002.4(2):126-133.

POWELL DW, PINCHUK IV, SAADA JI. et al. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol,2011 , 73; 213-237. doi; 10. 1146/annurev. physiol. 70.113006.100646.

EBIHARA N, NAKAYAMA M, TOKURA T, et al. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Exp Eye Res, 2009, 89

(2):256-262.

ZHENG L, LV Z, GONG Z, et al. Fnl4 hepatic progenitor cells are associated with liver fibrosis in biliary atresia. Pediatr Surg Int.2017,33(5) :593-599.


Refbacks

  • There are currently no refbacks.